Why the study?
Does B-type natriuretic peptide (BNP) testing aid in the diagnosis and prognosis of heart failure?
Does B-type natriuretic peptide (BNP) testing aid in the diagnosis and prognosis of heart failure?
Answers are grounded in this paper and cite their sources.
BNP is a valuable diagnostic and prognostic biomarker in heart failure, with levels <100 pg/mL effectively excluding acute decompensation.
B-type natriuretic peptide (BNP) is a cardiac neurohormone released as preproBNP and then enzymatically cleaved to N-terminal-proBNP and BNP upon ventricular myocyte stretch. Blood measurements of BNP have been used to identify patients with heart failure. Currently, BNP assay is used as a diagnostic and prognostic aid in congestive heart failure. In general, a BNP level <100 pg/mL excludes acutely decompensated heart failure. This article sorts out the literature concerning the practical use of BNP in a variety of clinical scenarios.
No takes yet. Share an insight, caveat, or question.
Peter A. McCullough (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: